Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4514-4517
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4514
Vascular endothelial growth factor pathway’s influence on bevacizumab efficacy in metastatic colorectal cancer treatment
Yuan Qin, Fu-Yuan Ma, Zhi Zhang, Chen-Hao Zhao, Biao Huang
Yuan Qin, Fu-Yuan Ma, Zhi Zhang, Chen-Hao Zhao, Biao Huang, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China
Author contributions: Huang B and Qin Y designed this study; Qin Y and Ma FY contributed to the writing and editing of the manuscript; Zhang Z and Zhao CH conducted the reference analyses.
Supported by The Natural Science Foundation of Zhejiang Province, No. LQ23H050005; The Scientific Research Project of Zhejiang Provincial Education Department, No. Y202250731 and No. Y202353130; China Students’ Innovation and Entrepreneurship Training Program, No. 202310338044; and China Postdoctoral Science Foundation, No. 2022M721720.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Biao Huang, PhD, Research Fellow, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 928, No. 2 Street, Qiantang District, Hangzhou 310018, Zhejiang Province, China. jswxhb@163.com
Received: July 24, 2024
Revised: September 17, 2024
Accepted: September 25, 2024
Published online: November 15, 2024
Processing time: 92 Days and 21.7 Hours
Core Tip

Core Tip: In the management of colorectal carcinoma, bevacizumab wields its therapeutic impact via the neutralization of vascular endothelial growth factor (VEGF), a paramount mediator of intratumoral angiogenesis. This inhibitory action on VEGF obstructs neovascularization, consequently sequestering the essential sustenance of nutrients and oxygen requisite for tumoral proliferation and viability. Contrarily, the interaction between programmed death-ligand 1 and VEGF receptor 2 catalyzes the genesis of novel vasculature that sustains and nurtures the neoplasm, thereby potentiating angiogenic processes.